CRISPR-Based Delivery System Generates CAR T Cells In Vivo
October 14, 2026
A two-vector delivery system generates tumor-targeting CAR T cells directly inside the body, achieving complete responses in mouse cancer models
3 min read
False
Advertisement
Cell & Gene
Bringing CAR T Closer to Home
October 13, 2026
CAR T Vision aims to widen access to cell therapy by expanding community-based delivery, easing operational barriers, and building sustainable funding models
7 min read
Caribou Halts Allogeneic CAR T Programs as Funding Pressures Mount
October 12, 2026
“Caribou’s story has taken a heartbreaking turn,” says CEO Rachel Haurwitz, with the CRISPR-focused biotech set to discontinue vispa-cel and CB-011, and reduce its workforce
2 min read
Prula-cel Shows Early Promise in Lupus
October 8, 2026
Adicet Bio reports 12-month remission and renal response data for its allogeneic gamma delta CAR T therapy
2 min read
Video: Sitting Down With… John Tomtishen
October 7, 2026
Catalent’s John Tomtishen discusses his path into cell therapy and the evolving approaches to CMC, manufacturing, and commercialization
1 min read
Pregnancy After CAR T Shows Early Promise
By Mouj Hijazi
October 7, 2026
No autoimmune disease flares occurred across 14 pregnancies after CAR T-cell therapy, with 8 healthy babies born and 5 pregnancies ongoing.
3 min read
When CAR T Cells Linger in the Gut
By Mouj Hijazi
October 7, 2026
Persistent CAR T cells and widespread immune disruption may help explain a rare form of severe intestinal inflammation after BCMA-directed therapy
3 min read
Building a CAR-T CMC Strategy on a Limited Budget
By Kate Fynes
October 6, 2026
Early developers do not need a finalized commercial process before first-in-human studies, but they do need a clear plan for managing cost, scalability, comparability, and future manufacturing changes
7 min read
Development & Clinical
Cell & Gene
Interviews
Business & Trends
Technology & Manufacturing
Power List
Musings from The Power List: Fabian Gerlinghaus
October 1, 2026
Cellares Co-Founder and CEO discusses why the future of cell therapy depends on rethinking how therapies are made
3 min read
In vivo CAR‑T – Reimagining Immune Engineering with Direct Cell Reprogramming
September 30, 2026
How direct T-cell reprogramming could simplify CAR-T manufacturing, expand patient access, and extend cellular immunotherapy to new indications
10 min read
